Acomplia diet pill  is the first in a new class of compounds under development to block receptors found in the brain and in fat tissue known as cannabinoid type 1 (CB1). These receptors control hunger and tobacco addiction. Chronic overeating and smoking sends them into overdrive. Blocking the CB1 receptors dramatically reduces such cravings. Results of a two-year clinical trial in the U.S. showed patients given Acomplia lost an average of 19 pounds, compared with five pounds for patients given a placebo. Those on Acomplia also reported higher levels of HDL, the good cholesterol, lower levels of triglycerides, and improved sensitivity to insulin. All are important in keeping heart disease at bay. “This could be a paradigm-shifting drug,” says Dr. Louis J. Aronne, president of the North American Society for the Study of Obesity.

The medicine is approved in 42 countries and is sold in 20 as a treatment for obesity and overweight patients with associated heart risk factors, the company said.

The June 13 decision suggested Zimulti won’t win the FDA’s backing after three patients committed suicide in medical trials. European Union regulators said this month that they will review the medicine for psychiatric side effects, and Sanofi said today it submitted more data to the London-based European Medicines Agency.

We are proud to announce that 4Rx are now able to offer Acomplia from our website.

Acomplia has been keenly awaited, as it promises a new hope for many people who have had little or no luck with other diets or treatments.

It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction.

The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.

Cincinnati, OH, March 9, 2004 - C Researchers at the University of Cincinnati College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly reduced post-cessation weight gain at 10 weeks, and was well-tolerated.

Acomplia / Rimonabant - Technical Information

Acomplia was recently approved in the UK as a controlled medication and is under application in the US. The active ingredient in Acomplia is rimonabant, which is a CB1 endocannabinoid receptor antagonist.
(The endocannabinoid system is in the part of the brain that regulates metabolism, energy levels and appetite).

Accomplia product has, since June 2006, been authorized for the European Market

How to loose weight its the main question.

Everybody is asking this .Now its very important to take the right decision  when you start a treatment to loose weight.

If you want to know how, its simple you can find plenty of advices ,treatments and stuff……But do they really work?

The safest way to loose weight its to make lot of exercises and follow a strict diet.But this is a hard method trust me,

I already tried it .

But there is always a second chance so I tried Acomplia.

A friend of mine living in France told me about the new weight loss pill Acomplia or rimonabant (generic version of the drug) lunched by Sanofi Aventis.First moment i was septic concerning the diet pill ,but after that i started to read reviews about it and I was impressed.

I was worried of side effects but all the other customers suggested that there are few side effects and the results  are amazing.

So I started the treatment with Acomplia.The first days were very hard to pass.I had some serious problems with my stomach.But i Found out later it was normal to feel like that because of my metabolism  that was changing .

After this hard period had no other problems and obtained great results with acomplia.

So my advice if you want to loose weight is to take acomplia.

I know others that used phentermine or Xenical and had serious problems.

I saw a picture with a lady taking Xenical and it was awful.I think acomplia  its the best solution on the market right now.You can loose weight fast without risks.

I hope you all have the same experience ,and I will be happy to read your opinion about the new weight loss pill.

If you want to know more just leave a reply and i will be happy to guide you and explain how i followed the prescription

There has been talk for some time about a new experimental weight loss drug called Acomplia or Rimonabant. It is now being said that Acomplia or Rimonabant is getting closer to approval by the FDA.

The new drug has been undergoing testing and trials over the last few years. The tests with Acomplia against a placebo has shown that it is effective and does show sustained weight loss after two years of taking the drug. The overweight adults who took Acomplia had lost significantly more weight than those not taking Acomplia. The test also showed that it had increased the levels of HDL cholesterol which is good for you.

• We supply you with many useful tools to track your condition. The latest in this series is BMI Calculator
• We manage weight loss forum - we care about your opinion and invite you to participate in our forum!
• Additionally, on our site you will find many articles written by our specialists and also by our visitors - we invite you to send us your article!

Acomplia Rimonabant in Long Term Weight Loss

Efficacy and safety in long-term use is important feature of any antiobesity drug. Some potential antiobesity medications have proved effective in the first six months of treatment only to lose effectiveness as subjects develop resistance to treatment.

Acomplia (Rimonabant) has proven effective in taking off weight and keeping it off for at least 3 years, a result not shared by other diet medications. The three major weight loss drugs act in very different ways: Meridia targets specific chemicals in the brain to reduce appetite, while Xenical helps prevent the absorption of fats from the foods users eat. Acomplia targets what is thought to be the brain’s pleasure center to reduce food cravings.

Several readers of the Acomplia Report have emailed us this past week with news that the highly anticipated diet pill has been found in pharmacies in Los Algodones, just across the border from Yuma, AZ; Tijuana, just across the border from California; and Nuevo Laredo, just across the Texas border.

At this point, buying Acomplia in Mexican pharmacies appears to be a hit-or-miss proposition, with some pharmacies telling prospective customers they had not heard of the diet drug or had not received it yet. And we have had no reports of anyone acquiring Acomplia from a Mexican pharmacy by mail.

Mexican prices for the diet drug reported to the Acomplia Report were in the $100 range for 28 pills, making purchases in Mexican border towns — if a visitor either lives just across the border or is in Mexico on holiday — a less expensive option than purchasing the diet pill by mail order from Europe.

“I am at least 50 pounds overweight. No matter how much I try it is impossible to lose weight.”

“I am interested in losing 30 pounds and have been trying so hard, but nothing seems to keep it off.”

These and other personal stories filled WebMD’s email boxes in response to a recent news article, titled “Experimental Diet Drug Acomplia Has Staying Power,” about a new weight loss drug called rimonabant. The article generated far more responses than any other WebMD news report in recent memory, including those about weight loss and about other promising drugs.

The medication, also known as Acomplia, is still being tested and isn’t on the market. Yet reports about the drug’s possible benefits — which include not only suppressing appetite but also curbing the urge to smoke and improving cholesterol and blood sugar levels — have many WebMD users clamoring for it. “When can I go on this new great drug?” asked one. “I’m overweight and need help fast!”

The answer is that the drug’s manufacturer, Sanofi-Aventis, plans to apply for FDA approval in 2005. A decision by the agency will then take up to 10 months. If everything proceeds smoothly and the FDA gives its blessing, the drug could be on the U.S. market sometime in 2006. The company also hopes to get approval to sell the drug in Europe beginning in 2006.

Plenty of things can hold up or derail drug approvals, though, including concerns about safety, a subject that many WebMD users asked about. So far the main side effects seem to be nausea and dizziness, which were bothersome enough to cause some people participating in studies to drop out. What’s more, no one yet knows what risks the medication might pose with long-term use, which appears necessary to keep weight off.

Another common question was how to volunteer for studies. The manufacturer says none is open to new participants.

Few users asked what is perhaps the most important question: Is this really the miracle pill that many news reports have portrayed it to be? Known as a cannabinoid type I (CB1) blocker, it’s the first of an entirely new class of drugs, which works by blocking a pleasure center in the brain. From the standpoint of researchers, the drug is clearly a breakthrough.

But from the standpoint of people trying to lose weight, it’s something less. Researchers report that people taking the drug for two years lost an average of 19 pounds and 3 inches off their waists, compared with about 5 pounds and 1.5 inches among those who took a placebo. A benefit for sure, but hardly a miracle.

It’s worth remembering that the two drugs currently approved for weight loss, Meridia (sibutramine) and Orlistat (xenical), were also once hailed by the media and others as answers to obesity. But they ended up having much more modest effects. And then there’s the drug combination of fenfluramine and phentermine, known as fen-phen. Frenzy over fen-phen swept the U.S. until researchers discovered that the drug combo was causing heart valve problems. As a result, fenfluramine and its cousin Redux, another weight loss drug, were pulled off the market.

Rimonabant, perhaps in combination with other drugs, may in fact prove to be a useful tool in the fight against obesity and its adverse health effects. But it’s not going to be the magic bullet that many users are evidently hoping for. Their overwhelming response to the WebMD article is a reminder of how difficult and frustrating the battle with weight often is. We owe it to them not to give false hope that a pill — however promising — is the answer to their prayers.

Related Articles

rimonabant online

Buy acomplia

Order rimonabant acomplia

New weight loss drug Rimonabant can now be sold in the UK under the brand name Acomplia - who can get it and what does it do?

Rimonabant available as Acomplia in the UK

Rimonabant, a new weight loss drug to be marketed under the name Acomplia, has recently been approved by the EU and is available to patients in the UK as of 28th June 2006. The United Kingdom is, in fact, the very first place that Acomplia will be available, though it is likely to be a couple of years before the drug is available on the NHS.

Who is Acomplia For?

Clinical trials have found that Rimonabant can help overweight and obese people to lose weight. It was also found that the drug could reduce the risk of cardiovascular heart disease and diabetes, and be of help to people who are trying to stop smoking.

As of June 28th, Acomplia is available only to private patients with prescription, as the drug is currently awaiting approval of the National Institute for Health and Clinical Excellence (NICE) which is expected to take two years. If Acomplia is approved it is likely that obese (BMI over 30) patients, and overweight (BMI over 25) patients considered to be at high risk of type 2 diabetes or cardiovascular disease, could be offered the tablets.

However it has been noted that this weight loss treatment could cost the NHS billions, with each Acomplia tablet costing £1.97 - £55.20 per patient per month.

How Does Rimonabant Work?

Rimonabant targets an area in the brain called the Endocannabinoid System. It blocks the receptors in this area, meaning that Cannabinoids (chemical compounds containing ‘hungry’ messages) cannot reach the system. This lowers the intake of food, resulting in weight loss.

The Endocannabinoid system affects the regulation of energy use, the breaking down of sugars, lipids and of the regulation of body weight and metabolism.

Rimonabant targets visceral fat, a layer of fat which forms around internal organs. Reducing this layer of fat has been found to stem the production of harmful substances (such as cholesterol), which prevent the body responding to insulin. This effectively means that Rimonabant can lower the risk of diabetes and cardiovascular heart disease.

Is it Effective?

Trials of Rimonabant over the last few years have shown it to be an effective weight loss aid for some people. It was found that, of those taking 20mg tablets of Rimonabant, a third lost over 10% of their initial body weight, while over 60% lost over 5%. Average waist measurements are reported to have reduced by between 6 and 9 cm (3-4 inches).

Patients followed a low calorie diet while taking the drug, and achieved better results than a control group following a low calorie diet and taking a placebo.

Participants in these trials also showed improved glucose control, cholesterol and triglyceride measurements from blood fats. These results show improvements of beyond what is expected from normal weight loss. For this reason, Rimonabant is believed to have positive effects on these measures. High-Density lipoprotein cholesterol (The good cholesterol) measures had also improved beyond expected levels.

Side Effects and Maintenance

Side effects of this drug are known to include diarrhoea, nausea and anxiety, this provoked a 15% drop out rate among participants in the trial.

For most patients Rimonabant only remained effective for weight loss for up to about 34 weeks, though continuous use of the drug has been shown to maintain the weight loss.

After ending their use of Rimonabant, most patients regained most of the weight they had lost.

Related Articles

Order rimonabant

rimonabant acomplia online

order rimonabant no prescription

Rimonabant acomplia

Overweight or obese people with diabetes who took the drug Acomplia for a year, in combination with diet and exercise, had modest but significant improvements in blood sugar control and cholesterol, along with modest weight loss.

Acomplia has not yet been approved for sale in the U.S., but it is being sold in Europe.

In the new study, 1,047 overweight or obese people with type 2 diabetes who were already on an oral diabetes drug were randomly assigned to also take either a placebo, 5 milligrams of Acomplia, or 20 milligrams of Acomplia daily.

After a year of treatment, patients who took the higher dose of Acomplia had lost an average of 11.7 pounds, compared with 3 pounds among patients in the placebo group and 5 pounds among patients who took the lower dose of the drug.

Patients taking the higher dose of Acomplia also showed greater improvements in waist circumference, HDL “good” cholesterol levels, triglyceride (blood fat) levels, and blood sugar control.

The study appears in the Oct. 27 online edition of the journal The Lancet. It was funded by Acomplia’s maker, Sanofi-Aventis. Sanofi-Aventis is a WebMD sponsor.

The researchers reported that improvements in cholesterol and blood sugar were twice what would have been expected from weight loss alone, indicating that the weight loss drug has an independent effect on these diabetes risk factors.

Second Opinion on Study

Two diabetes experts who wrote an editorial accompanying the study conclude that it is premature to assume that Acomplia has a direct impact on diabetes risk factors, over and above its ability to promote weight loss.

Stephen Cleland and Naveed Sattar also express concern about the high dropout rate among study participants. Of the 1,047 patients who were recruited, only 692 (66%) completed the one-year study.

The dropout rate was roughly the same for patients in all three arms of the study, and most patients did not drop out because of side effects.

But 11 patients (3%) who took the higher dose of Acomplia cited depressiondepression as a reason for dropping out of the study. None of the patients in the lower-dose arm of the study dropped out because of depression; three patients (0.9%) in the placebo arm dropped out for this reason.

“The suggestion that [Acomplia] increases depression and anxiety is concerning,” Cleland and Sattar write.

More Options

The prescription weight loss drugs that are available in the U.S. are not routinely used for the treatment of type 2 diabetes because of worries about side effects.

Larry Deeb, MD, of the American Diabetes Association, tells WebMD that a safe and effective weight loss drug would be a welcome addition to the growing list of drugs used to treat type 2 diabetes.

“As a diabetes doctor I want my patients to follow a healthy lifestyle, which includes regular exercise and eating a healthy diet,” he says. “This has benefits over and above the impact on blood sugar. But the reality is that far too few patients take this advice, so we need as many therapeutic options as we can get.”

Acomplia may prove to be a useful drug for diabetes, he says, but it is far from a wonder drug.